In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes

Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52., Szeged, Hungary.
Antonie van Leeuwenhoek (Impact Factor: 1.81). 07/2008; 94(3):463-70. DOI: 10.1007/s10482-008-9263-x
Source: PubMed


Strains of five dermatophyte species (Microsporum canis, Microsporum gypseum, Trichophyton mentagrophytes, Trichophyton rubrum and Trichophyton tonsurans) were selected for testing against Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole (FCZ). Inhibition of microconidia germination and growth was detected with MICs of PAF ranging from 1.56 to 200 microg ml(-1) when it was used alone, or at constant concentration (100 microg ml(-1)) in combination with FCZ at from 0.25 to 32 microg ml(-1). The MICs for FCZ were found to be between 0.25 and 128 microg ml(-1). PAF caused a fungicidal effect at 200 microg ml(-1) and reduced growth at between 50 and 200 microg ml(-1). Total growth inhibition with fungistatic activity was detected at 64 microg ml(-1) of FCZ for M. gypseum, T. mentagrophytes, and T. tonsurans, and at 32 microg ml(-1) FCZ for M. canis and T. rubrum. PAF and FCZ acted synergistically and/or additively on all of the tested fungi except M. gypseum, where no interactions were detected.

Download full-text


Available from: Laszlo Galgoczy, Apr 17, 2015
  • Source
    • "Aala and collaborators [41] found good activity between allicin in combination with ketoconazole or fluconazole demonstrating a synergistic or additive interaction against dermatophytes. Galgóczy and coauthors [42] evaluated the in vitro antifungal activity against strains of dermatophytes, combining the protein (PAF) of Penicillium chrysogenum with fluconazole (FCZ). PAF and FCZ acted synergistically and/or additively on all of the tested fungi except Microsporum gypseum, for which no interactions were detected [42]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermatophytosis and superficial mycosis are a major global public health problem that affects 20–25% of the world’s population. The increase in fungal resistance to the commercially available antifungal agents, in conjunction with the limited spectrum of action of such drugs, emphasises the need to develop new antifungal agents. Natural products are attractive prototypes for antifungal agents due to their broad spectrum of biological activities. This study aimed to verify the antifungal activity of protocatechuic acid, 3,4-diacetoxybenzoic, and fourteen alkyl protocatechuates (3,4-dihydroxybenzoates) against Trichophyton rubrum and Trichophyton mentagrophytes and to further assess their activities when combined with fluconazole. Susceptibility and synergism assays were conducted as described in M38-A2 (CLSI), with modifications. Three strains of Trichophyton rubrum and three strains of Trichophyton mentagrophytes were used in this work. The pentyl, hexyl, heptyl, octyl, nonyl, and decyl protocatechuates showed great fungicidal effects, with minimum inhibitory concentration (MIC) values ranging from 0.97 to 7.8 mg/L. Heptyl showed a synergistic activity (FIC index ), reducing the MIC of fluconazole by fourfold. All substances tested were safe, especially the hexyl, heptyl, octyl, and nonyl compounds, all of which showed a high selectivity index, particularly in combination with fluconazole. These ester associations with fluconazole may represent a promising source of prototypes in the search for anti-Trichophyton therapeutic agents.
    Evidence-based Complementary and Alternative Medicine 06/2014; 2014(4). DOI:10.1155/2014/957860 · 1.88 Impact Factor
  • Source
    • "The extracellular, defensin-like antifungal proteins secreted by filamentous ascomycetes are interesting in this respect both in medicine and agriculture . These proteins have potent antifungal activity against potential human, plant and food-borne pathogenic fungal species [1] [2] [3], they could not have any toxic effects on plant and mammalian cells in vitro and in vivo [2] [4] [5], they can interact synergistically with other antifungal drugs and peptides [6] [7] [8], and they have high stability against protease degradation, high temperature and that they are active within broad pH range [1]. These facts and their low costs of production could make them promising candidates as a base of commercial biopesticides, medicines and food preservatives against harmful filamentous fungi [1] [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neosartorya fischeri NRRL 181 isolate secretes a defensin-like antifungal protein (NFAP) which has a remarkable antifungal effect against ascomycetous filamentous fungi. This protein is a promising antifungal agent of biotechnological value; however in spite of the available knowledge of the nature of its 5′-upstream transcriptional regulation elements, the bulk production of NFAP has not been resolved yet. In this study we carried out its heterologous expression in the yeast Pichia pastoris and investigated the growth inhibition effect exerted by the heterologous NFAP (hNFAP) on filamentous fungal isolates from human infections compared with what was caused by the native NFAP. P. pastoris KM71H transformant strain harboring the pPICZαA plasmid with the mature NFAP encoding gene produced the protein. The final yield of the hNFAP was sixfold compared to the NFAP produced by N. fischeri NRRL 181. Based on the signal dispersion of the amide region, it was proven that the hNFAP exists in folded state. The purified hNFAP effectively inhibited the growth of fungal isolates belonging to the Aspergillus and to the Fusarium genus, but all investigated zygomycetous strain proved to be insusceptible. There was no significant difference between the growth inhibition effect exerted by the native and the heterologous NFAP. These data indicated that P. pastoris KM71H can produce the NFAP in an antifungally active folded state. Our results provide a base for further research, e.g., investigation the connection between the protein structure and the antifungal activity using site directed mutagenesis.
    Protein Expression and Purification 11/2013; 94:79-84. DOI:10.1016/j.pep.2013.11.003 · 1.70 Impact Factor
  • Source
    • "The ␤-defensin-like antimicrobial peptides with PAF-cluster are interesting in practical respect, and their potential applications are intensively studied both in medical and agricultural fields. Their following features that they have potent antifungal activity against potential human and plant pathogenic fungal species [12], that they could not have any toxic effects on plant and mammalian cells in vitro [32] [33], that they can interact synergistically with other antifungal drugs and peptides [10] [11] [23], and their low costs of production could make them suitable as active ingredients of commercial biopesticides and medicines [21] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Putative antifungal peptide encoding genes containing Penicillium chrysogenum antifungal protein (PAF) characteristic amino acid motifs were identified in 15 Fusarium isolates, representing 10 species. Based on the predicted sequences of mature peptides, discrepancy in one, two or three amino acids was observed between them. Phylogenetic investigations revealed that they show high amino acid sequence similarity to PAF and they belong to the group of fungal derived antifungal peptides with PAF-cluster. Ten from the 15 partially purified <10kDa peptide fraction of Fusarium ferment broths showed antifungal activity. The presence of approximately 6.3kDa molecular weight peptides was detected in all of the antifungally active ferment broths, and this peptide was isolated and purified from Fusarium polyphilaidicum. The minimal inhibitiory concentrations of Fusarium polyphilaidicum antifungal protein (FPAP) were determined against different filamentous fungi, yeasts and bacteria. Filamentous fungal species were the most susceptible to FPAF, but some yeasts were also slightly sensitive.
    Peptides 11/2012; 39:131-137. DOI:10.1016/j.peptides.2012.10.016 · 2.62 Impact Factor
Show more